Leukemia-targeting ligands isolated from phage-display peptide libraries. (Q33270272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Leukemia-targeting ligands isolated from phage-display peptide libraries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Jäger S

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Jahnke A

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Wilmes T

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Adebahr S

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Vögtle FN

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Delima-Hahn E

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Pfeifer D

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Lübbert M

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Trepel M

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

25 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

411-420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404548

24 December 2019

exact match

0 references

cites work

The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Therapeutic options for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Prognostically useful gene-expression profiles in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Libraries of peptides and proteins displayed on filamentous phage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Biopanning and rapid analysis of selective interactive ligands

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

In vivo phage display and vascular heterogeneity: implications for targeted medicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Organ targeting in vivo using phage display peptide libraries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Tumor targeting with a selective gelatinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Targeting the prostate for destruction through a vascular address

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

A tumor-homing peptide with a targeting specificity related to lymphatic vessels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Reversal of obesity by targeted ablation of adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Teratogenicity induced by targeting a placental immunoglobulin transporter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Anti-cancer activity of targeted pro-apoptotic peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Alpha 4 integrin antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (alpha 4 beta 1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatm

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404548

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17252013%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

24 December 2019

0 references

1 reference